Showing results (41-50 of 56) with videos related to
Sort By:
Pageof 6
Science (New York, N.Y.)|September 10, 2016
Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancersJared R Mayers, Margaret E Torrence, Laura V Danai, et al.Crystal Growth & Design|March 25, 2024
Comparison of N···I and N···O Halogen Bonds in Organoiodine Cocrystals of Heterocyclic Aromatic Diazine Mono-<i>N</i>-oxidesClifford W Padgett, Riley Dean, Audrey Cobb, et al.Cancers|August 29, 2024
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in MelanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignanciesBahram Forouzesh, Chris H Takimoto, Andrew Goetz, et al.Biorxiv : the Preprint Server for Biology|August 16, 2024
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesJohann S de Bono, Joseph Stephenson, Sharyn D Baker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignanciesEric K Rowinsky, Jinee Rizzo, Leonel Ochoa, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomasJames A Posey, M Wasif Saif, Ronda Carlisle, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignanciesAmita Patnaik, Eric K Rowinsky, Miguel A Villalona, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumorsAlejandro D Ricart, Lisa A Hammond, John G Kuhn, et al.Pageof 6